XenoPort Inc: Premium Company Profile

Introduction

XenoPort is a biopharmaceutical company with therapeutic focus in the areas of central nervous system (CNS) and gastrointestinal tract (GI). Its product pipeline is based on its proprietary Transported Prodrug technology platform, which is focused on improving upon the pharmacologic properties of currently available therapeutics.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

XenoPort's pipeline includes XP19986, indicated for gastro-esophageal reflux disease (Phase IIa) and spasticity (Phase I), and XP13512 indicated for Restless Legs Syndrome (Phase III) and neuropathic pain (Phase IIa). The key elements ofit's business strategy include: entering into strategic alliances with other pharmaceutical/biotechnology companies for discovery, development and commercialization of its product candidates; advancing clinical development of its product candidates; and Transported Prodrug to discover new product candidates. The company's total revenues increased at a CAGR of 99.2% during 2002-2006, from $0.7 million to $10.6 million. The company's only contributor to revenue growth during 2002-2006 was revenues from license, collaboration and others.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.

Report Highlights

[Studien Infos ausblenden]